Innoviva is acquiring La Jolla Pharmaceutical Company, a deal that reportedly includes two FDA-approved drugs. The acquisition is seen as a move by Innoviva to expand its presence in infectious diseases. The terms of the deal include a purchase price, but the amount is not consistently reported, with one outlet citing $149 million.